CLEC5A expressed on myeloid cells as a M2 biomarker relates to immunosuppression and decreased survival in patients with glioma
| العنوان: | CLEC5A expressed on myeloid cells as a M2 biomarker relates to immunosuppression and decreased survival in patients with glioma |
|---|---|
| المؤلفون: | Elias Boussouf, Michael Lim, Li Yi, Peidong Liu, Jiabo Li, Luqing Tong, Yuanxuan Xia, Xuejun Yang, John Choi, Christopher M. Jackson, Ayush Pant |
| المصدر: | Cancer Gene Therapy. 27:669-679 |
| بيانات النشر: | Springer Science and Business Media LLC, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, Cancer Research, medicine.medical_treatment, Central nervous system, Receptors, Cell Surface, Flow cytometry, 03 medical and health sciences, 0302 clinical medicine, Glioma, Biomarkers, Tumor, medicine, Humans, Lectins, C-Type, Myeloid Cells, neoplasms, Molecular Biology, Gene, Immunosuppression Therapy, medicine.diagnostic_test, business.industry, Mesenchymal stem cell, CLEC5A, Immunosuppression, Prognosis, M2 Macrophage, medicine.disease, Survival Analysis, nervous system diseases, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Cancer research, Molecular Medicine, Female, business |
| الوصف: | Glioma is the most common tumor in the central nervous system that portends a poor prognosis. Key genes negatively related to survival may provide targets for therapy to improve the outcome of glioma. Here, we report a protein-coding gene CLEC5A, which is the top 1 gene by univariate Cox regression analysis of 524 primary GBM samples. Expression of CLEC5A is significantly correlated with decreased overall survival in patients with glioma via large-scale analysis. An analysis of 2589 patient samples showed that CLEC5A expression is higher in (1) glioblastoma than in lower-grade glioma and nontumor tissue, (2) in the mesenchymal subtype than in other subtypes, and (3) in IDH1-wild type glioblastoma than in IDH1-mutated glioblastoma. Notably, this tumor-associated biomarker is expressed preferentially on myeloid cells over glioma cells. And it shows a strong co-expression with M2 macrophage biomarker. Furthermore, CLEC5A-associated genes are enriched in immunosuppressive biological processes. The silico flow cytometry also showed CLEC5A expression related to less tumor purity and more tumor-promoting leukocytes infiltration. In conclusion, we proposed a new M2 biomarker expressed on myeloid cells that may decrease survival in patients with glioma through immunosuppressive mechanisms. |
| تدمد: | 1476-5500 0929-1903 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::250726404ea17fdeb7ebcce0e70697d1Test https://doi.org/10.1038/s41417-019-0140-8Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....250726404ea17fdeb7ebcce0e70697d1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14765500 09291903 |
|---|